Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6NUQ1
UPID:
RINT1_HUMAN
Alternative names:
RAD50 interactor 1
Alternative UPACC:
Q6NUQ1; Q75MG9; Q75MH0; Q96IW8; Q9H229; Q9HAD9
Background:
RAD50-interacting protein 1, alternatively known as RAD50 interactor 1, plays a crucial role in cellular processes including membrane traffic regulation between the Golgi and the endoplasmic reticulum (ER). Its function is tied to its association in the NRZ complex, which is pivotal for SNARE assembly at the ER. Additionally, it is involved in cell cycle checkpoint control and is essential for telomere length maintenance.
Therapeutic significance:
RAD50-interacting protein 1 is linked to Infantile liver failure syndrome 3, a severe disorder characterized by acute liver failure in early life, often triggered by infections or fever, alongside skeletal anomalies. Understanding the role of RAD50-interacting protein 1 could open doors to potential therapeutic strategies for this life-threatening condition.